DEF 14A: MetaVia Inc. Seeks Shareholder Approval for Reverse Stock Split and Key Capital Raise to Maintain Nasdaq Listing and Fund Operations

MetaVia Inc. is calling for its 2025 Annual Meeting of Stockholders to vote on critical proposals including a reverse stock split to meet Nasdaq listing requirements and the approval of shares issued in a recent private placement to fund ongoing operations.

Summary

• MetaVia Inc. will hold its virtual 2025 Annual Meeting of Stockholders on Monday, June 30, 2025, at 10:00 a.m. Eastern Time.
• Key proposals include the election of two Class III directors, ratification of BDO USA, P.C. as the independent auditor, and an advisory vote on executive compensation.
• A significant proposal is to approve an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-30, at the Board's discretion, to increase the stock price and maintain Nasdaq listing compliance.
• The company received a Nasdaq Notice on May 29, 2025, indicating non-compliance with the Minimum Bid Price Requirement ($1.00 per share).
• Shareholders will also vote on the approval of issuing shares of Common Stock, equal to or exceeding 20% of outstanding shares, upon the exercise of 4,605,162 pre-funded warrants issued in a private placement to Dong-A Socio Holdings Co., Ltd. on May 8, 2025.
• The 2025 private placement generated gross proceeds of approximately $10.0 million, before deducting placement agent fees and related offering expenses.
• The Board of Directors unanimously recommends voting 'FOR ALL' in Proposal 1 and 'FOR' Proposals 2, 3, 4, 5, and 6.
• As of the Record Date (June 9, 2025), MetaVia had 19,588,351 shares of Common Stock outstanding and entitled to vote.
• Dong-A Socio Holdings Co., Ltd. and its affiliates beneficially own 75.7% of MetaVia's outstanding Common Stock, making MetaVia a 'controlled company' under Nasdaq rules.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the company's non-compliance with Nasdaq listing requirements, the necessity of a reverse stock split, and consistent net losses. While a capital raise provides some liquidity, it comes with significant dilution and the need for further shareholder approval, indicating ongoing financial challenges. The 'controlled company' status also limits independent governance.

Positives

• The company is actively addressing its Nasdaq Minimum Bid Price Requirement non-compliance through a proposed reverse stock split.
• A recent private placement on May 8, 2025, raised approximately $10.0 million in gross proceeds, providing capital for operations.
• The Board has adopted robust corporate governance practices, including Corporate Governance Guidelines, an Insider Trading Policy, and a Compensation Recovery Policy.
• The Board's audit committee, compensation committee, and nominating and corporate governance committee are in compliance with Nasdaq listing requirements despite the company's 'controlled company' status.

Negatives

• MetaVia Inc. is currently non-compliant with Nasdaq's Minimum Bid Price Requirement, having received a notice on May 29, 2025.
• The necessity of a reverse stock split indicates a significantly low share price, which can carry a negative perception among investors.
• The company's net income (loss) has been negative for the past three fiscal years, with a loss of $(27,592) thousand in 2024, $(12,470) thousand in 2023, and $(13,967) thousand in 2022.
• Total Shareholder Return has declined over the past three fiscal years, from $1.96 in 2022 to $0.69 in 2024 (based on an initial $100 investment).
• Failure to obtain stockholder approval for the issuance of shares underlying pre-funded warrants (Proposal 5) would prevent their exercise and incur substantial additional costs for the company, potentially impacting funding for clinical development.

Risks

• The reverse stock split may not result in a sustained increase in the per share market price of the Common Stock, or the total market capitalization may decline.
• A reverse stock split can carry a negative perception among some investors, analysts, and market participants.
• The reverse stock split could adversely affect the liquidity of the Common Stock due to a reduced number of outstanding shares.
• Stockholders owning fewer than 5 to 30 shares (depending on the final ratio) prior to the split will receive cash for fractional shares and cease to be stockholders.
• The increase in authorized but unissued shares after the reverse stock split could lead to future dilutive equity financing transactions or be used to deter hostile takeover attempts.
• Failure to regain compliance with Nasdaq's Minimum Bid Price Requirement could lead to delisting, adversely affecting the company's ability to raise capital and the liquidity/value of its stock.
• Recent amendments to Nasdaq Listing Rule 5810 could make the company ineligible for compliance periods if it has effected multiple reverse stock splits with a cumulative ratio of 1 for 250 or more over the prior two years, or any split over the prior one year.
• The company is obligated to hold meetings every four months to seek stockholder approval for the warrant issuance if not obtained at the Annual Meeting, incurring additional costs.

Future Outlook

MetaVia Inc. intends to implement a reverse stock split to increase its market price and maintain its Nasdaq listing, aiming to attract a broader range of institutional investors. The company expects to submit a request for a second 180-calendar day extension to regain Nasdaq compliance if needed. Future funding for operations, including the clinical development of DA-1726 for obesity, is contingent on obtaining stockholder approval for the issuance of shares underlying pre-funded warrants from the recent private placement.

Management Comments

• "The Board of Directors unanimously recommends that you vote FOR ALL in Proposal 1 and FOR Proposal 2, Proposal 3, Proposal 4, Proposal 5 and Proposal 6."
• "We believe that a reverse stock split will enhance our ability to maintain our listing on Nasdaq and comply with the Minimum Bid Price Requirement."
• "The Board only intends to implement a reverse stock split to the extent it believes necessary to maintain the Company’s listing on Nasdaq."
• "We continue to monitor the closing bid price of the Common Stock and consider our available options to maintain compliance with the Minimum Bid Price Requirement."

Industry Context

The need for a reverse stock split and a capital raise through private placement with warrants suggests that MetaVia Inc., a biopharmaceutical company, is facing challenges common to smaller or developing companies in the sector, particularly in maintaining public market listing standards and securing funding for R&D (e.g., DA-1726 for obesity). The reliance on a major shareholder (Dong-A) for significant capital infusion and its 'controlled company' status highlights a common funding model in the biotech industry where strategic partners or large investors play a dominant role.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Mr. Glickman, Mr. Koven, and Dr. Tursi were associated with Aralez and Endo, both of which filed for Chapter 11 bankruptcy in 2018 and 2022, respectively. This is noted as 'Involvement in Certain Previous Legal Proceedings' but does not indicate current legal proceedings against MetaVia Inc.

Related Party Transactions

• Entities affiliated with Dong-A (Dong-A and Dong-A Socio Holdings Co., Ltd.) are beneficial owners of 75.7% of MetaVia's Common Stock.
• On June 23, 2024, MetaVia entered into a Securities Purchase Agreement (2024 Private Placement) with Dong-A and another institutional investor, issuing 2,544,530 shares of Common Stock, Series A Warrants, and Series B Warrants to Dong-A.
• On May 8, 2025, MetaVia entered into another Securities Purchase Agreement (2025 Private Placement) with Dong-A and Dong-A Holdings, issuing 9,479,345 shares of Common Stock and 4,605,162 pre-funded warrants, generating approximately $10.0 million in gross proceeds.

Stakeholder Impact

• **Shareholders**: Will experience significant dilution if the reverse stock split is approved and implemented, and further dilution upon the exercise of pre-funded warrants. Those holding fractional shares post-split will cease to be shareholders. The potential for delisting poses a risk to liquidity and share value.
• **Management/Employees**: Executive compensation policies are in place, including a clawback policy. The company's ability to fund operations, including clinical development, impacts job security and growth opportunities.
• **Creditors**: The capital raise provides some financial stability, but ongoing losses and Nasdaq compliance issues could raise concerns about the company's long-term viability.
• **Nasdaq**: The company is actively working to regain compliance with listing rules, which is crucial for its public market presence.

Next Steps

• Hold the virtual 2025 Annual Meeting of Stockholders on June 30, 2025, to vote on the proposed resolutions.
• If approved, the Board will determine the specific ratio (1-for-5 to 1-for-30) and timing for the reverse stock split within one year of stockholder approval.
• If stockholder approval for Proposal 5 is not obtained at the Annual Meeting, the company is obligated to hold a meeting every four months thereafter to seek approval until it is obtained.
• The company will file a Current Report on Form 8-K with the SEC within four business days of the Annual Meeting to disclose final voting results.
• The company will continue to monitor its compliance with Nasdaq listing standards and may appeal any delisting determination.

Key Dates

Recommendation

Keywords

Proxy Statement, Reverse Stock Split, Nasdaq Listing, Capital Raise, Private Placement, Warrants, Corporate Governance, Executive Compensation, Shareholder Meeting, SEC Filing, Biopharmaceutical, Clinical Development